Jacobson Pharma Corporation Ltd
HKEX:2633
Income Statement
Earnings Waterfall
Jacobson Pharma Corporation Ltd
Income Statement
Jacobson Pharma Corporation Ltd
| Mar-2017 | Sep-2017 | Mar-2018 | Sep-2018 | Mar-2019 | Sep-2019 | Mar-2020 | Sep-2020 | Mar-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Sep-2022 | Mar-2023 | Sep-2023 | Mar-2024 | Sep-2024 | Mar-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||
| Interest Expense |
14
|
26
|
46
|
65
|
66
|
130
|
55
|
16
|
30
|
27
|
0
|
26
|
32
|
61
|
89
|
79
|
52
|
41
|
0
|
|
| Revenue |
1 256
N/A
|
1 424
+13%
|
1 549
+9%
|
1 622
+5%
|
1 478
-9%
|
2 235
+51%
|
1 571
-30%
|
2 267
+44%
|
1 446
-36%
|
1 501
+4%
|
1 923
+28%
|
1 596
-17%
|
1 850
+16%
|
1 268
-31%
|
1 401
+10%
|
1 468
+5%
|
1 563
+6%
|
1 577
+1%
|
1 533
-3%
|
|
| Gross Profit | ||||||||||||||||||||
| Cost of Revenue |
(699)
|
(832)
|
(931)
|
(964)
|
(803)
|
(1 210)
|
(881)
|
(1 311)
|
(885)
|
(933)
|
(1 182)
|
(975)
|
(1 074)
|
(729)
|
(814)
|
(847)
|
(892)
|
(884)
|
(854)
|
|
| Gross Profit |
557
N/A
|
591
+6%
|
618
+4%
|
657
+6%
|
675
+3%
|
1 025
+52%
|
690
-33%
|
956
+39%
|
561
-41%
|
568
+1%
|
742
+31%
|
621
-16%
|
775
+25%
|
539
-30%
|
586
+9%
|
620
+6%
|
671
+8%
|
693
+3%
|
679
-2%
|
|
| Operating Income | ||||||||||||||||||||
| Operating Expenses |
(331)
|
(331)
|
(338)
|
(333)
|
(336)
|
(519)
|
(387)
|
(514)
|
(397)
|
(355)
|
(457)
|
(375)
|
(434)
|
(270)
|
(309)
|
(309)
|
(304)
|
(260)
|
(265)
|
|
| Selling, General & Administrative |
(333)
|
(333)
|
(340)
|
(336)
|
(341)
|
(531)
|
(402)
|
(592)
|
(408)
|
(400)
|
(508)
|
(400)
|
(459)
|
(298)
|
(328)
|
(332)
|
(335)
|
(324)
|
(328)
|
|
| Research & Development |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Operating Expenses |
2
|
1
|
2
|
3
|
6
|
12
|
15
|
79
|
11
|
45
|
55
|
26
|
24
|
28
|
19
|
23
|
31
|
64
|
63
|
|
| Operating Income |
226
N/A
|
260
+15%
|
280
+8%
|
324
+16%
|
339
+5%
|
507
+49%
|
303
-40%
|
442
+46%
|
164
-63%
|
213
+30%
|
284
+34%
|
246
-14%
|
341
+39%
|
269
-21%
|
277
+3%
|
311
+12%
|
367
+18%
|
433
+18%
|
414
-4%
|
|
| Pre-Tax Income | ||||||||||||||||||||
| Interest Income Expense |
(8)
|
(17)
|
(29)
|
(45)
|
(35)
|
(53)
|
(48)
|
(60)
|
(35)
|
(27)
|
11
|
(15)
|
(22)
|
(45)
|
(57)
|
(58)
|
(54)
|
(56)
|
(41)
|
|
| Non-Reccuring Items |
3
|
1
|
0
|
(0)
|
5
|
13
|
8
|
9
|
91
|
8
|
0
|
0
|
22
|
26
|
6
|
2
|
(2)
|
(3)
|
(2)
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(38)
|
0
|
(5)
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
221
N/A
|
244
+10%
|
251
+3%
|
280
+11%
|
309
+11%
|
467
+51%
|
263
-44%
|
391
+49%
|
221
-44%
|
195
-12%
|
259
+33%
|
231
-11%
|
337
+46%
|
250
-26%
|
226
-10%
|
255
+12%
|
311
+22%
|
374
+20%
|
372
0%
|
|
| Net Income | ||||||||||||||||||||
| Tax Provision |
(40)
|
(39)
|
(46)
|
(54)
|
(56)
|
(83)
|
(46)
|
(61)
|
(34)
|
(38)
|
(50)
|
(44)
|
(61)
|
(43)
|
(41)
|
(44)
|
(58)
|
(73)
|
(69)
|
|
| Income from Continuing Operations |
181
|
205
|
205
|
225
|
254
|
383
|
217
|
330
|
186
|
157
|
209
|
188
|
276
|
207
|
186
|
210
|
253
|
301
|
303
|
|
| Income to Minority Interest |
(2)
|
(2)
|
(3)
|
(6)
|
(8)
|
(13)
|
(3)
|
(13)
|
(13)
|
(5)
|
461
|
(10)
|
448
|
0
|
11
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
179
N/A
|
203
+13%
|
202
0%
|
219
+9%
|
251
+14%
|
378
+51%
|
216
-43%
|
318
+48%
|
174
-45%
|
151
-13%
|
209
+38%
|
178
-15%
|
234
+32%
|
251
+7%
|
269
+7%
|
267
-1%
|
253
-5%
|
301
+19%
|
303
+1%
|
|
| EPS (Diluted) |
0.11
N/A
|
0.11
N/A
|
0.11
N/A
|
0.12
+9%
|
0.13
+8%
|
0.19
+46%
|
0.11
-42%
|
0.16
+45%
|
0.09
-44%
|
0.08
-11%
|
0.1
+25%
|
0.09
-10%
|
0.13
+44%
|
0.13
N/A
|
0.14
+8%
|
0.13
-7%
|
0.13
N/A
|
0.15
+15%
|
0.15
N/A
|
|